Skip Navigation
Skip to contents

SSBH 2022

Today : 2025.04.04
D- +1044
Day 2
May 27(Fri)
09:00-09:50
Plenary Lecture 1 E
Channel 1 (Vista Hall 1) Overview
Professor. Henry M. Kronenberg is currently Chief of Endocrine Unit at the Massachusetts General Hospital and Professor of Medicine at the Harvard Medical School. Bone forming cells, traditionally termed osteoblasts, are generated by different cohorts of skeletal stems cells that arise from different embryonic specifications, which operate in the prenatal and/or adult skeleton under the control of multiple regulators. Essential role of skeletal stem cells has been generally established for development, growth, and maintenance of the skeleton. A large number of bone-forming stem cell populations have been reported with various characteristic markers. In this plenary session, he will give us a keynote lecture about the skeletal stem and precursor cells in the osteoblast lineage identified to date.
Chairperson(s)
Ho-Yeon Chung (Kyung Hee University, Korea)
09:00-09:50 Skeletal Stem and Precursor Cells in the Osteoblast Lineage Henry M. Kronenberg (Harvard Medical School, USA)
Day 2
May 27(Fri)
09:55-11:10
Symposium 1. A Deep Dive into Controversies in Osteoporosis E
Channel 1 (Vista Hall 1) Overview
We organized a session with three experts to deal with issues encountered in clinical practice according to the increase in the number of osteoporosis patients and expansion of the choice of treatments. Prof. Sang Min Kim, the first speaker, will talk about the osteoporosis treatment strategy in patients with fractures that occurred during osteoporosis treatment based on research and clinical experience on fragility fractures. The second speaker, Prof. Alexander J. Rodriguez, who has lots of research experience on osteoporosis treatments and cardiovascular safety, will share findings of years of research. Lastly, Prof. Jeonghoon Ha will talk about the comparison of the efficacy of anti-osteoporosis treatments in Asians and non-Asians. While the introduction of Romosozumab raises interest in anabolic agents, there are concerns about cardiovascular complications. This session can be an opportunity to learn and understand the efficacy and safety of osteoporosis treatments, including romosozumab.
Chairperson(s)
Chan Soo Shin (Seoul National University, Korea), Seong-Hwan Moon (Yonsei University, Korea)
09:55-10:20 Fracture during Osteoporosis Medication: Switching to Anabolic Agent Sang-Min Kim (Korea University, Korea)
10:20-10:45 Cardiovascular Safety of Current Anti-Osteoporosis Medications: A Matter of Debate Alexander J. Rodríguez (Monash University, Australia)
10:45-11:10 Comparison of Efficacy of Anti-Osteoporosis Treatment in Asians and Non-Asians Jeonghoon Ha (The Catholic University of Korea, Korea)
Day 2
May 27(Fri)
11:20-12:35
Symposium 3. Recent Clinical Update in Osteoporosis Management K
Channel 1 (Vista Hall 1) Overview
In this session, we will introduce the latest updates in clinical practice of osteoporosis. First, Professor Kyung-Hwa Park, Department of Oncology, Korea Medical University, will introduce you to how to manage bone loss, which is commonly encountered during chemotherapy, based on various clinical experiences. Next, regarding osteonecrosis of jaw, which can be a problem with long-term use of anti-resorptives, the Korean Society for Bone and Mineral Research and the Korean Society for Oral and Maxillofacial Surgery recently published a revised version of the postion statement. In this regard, Professor Jinwoo Kim of Ewha Medical University, who played a major role in the revision work, will tell you in detail. Lastly, with recent technological developments, various methods have been introduced to diagnose osteoporosis. Professor Kyung-Min Kim, Department of Endocrinology and Metabolism, Yonsei University College of Medicine, will introduce various methods that are being tried recently in diagnosing osteoporosis and predicting fractures. We have prepared interesting and fruitful content, so please participate.
Chairperson(s)
Myung Hoon Hahn (Areumcheil Hospital, Korea), Dong Jin Chung (Chonnam National Univeristy, Korea)
11:20-11:45 Management of Bone Health in Cancer Treatment-Induced Bone Loss Kyong Hwa Park (Korea University, Korea)
11:45-12:10 Medication-Related Osteonecrosis of the Jaw: 2021 Position Statement of the KSBMR and KAOMS Jin-Woo Kim (Ewha Womans University, Korea)
12:10-12:35 Novel Methods and Approaches for Assessing Osteoporosis and Fracture Risk Kyoung Min Kim (Yonsei University, Korea)
Day 2
May 27(Fri)
12:40-12:55
Sponsored Lecture 1 [Amgen] K
Channel 1 (Vista Hall 1)
Chairperson(s)
Yong-Ki Min (Sungkyunkwan University, Korea)
12:40-12:55 Winning Combinations; Sequential Drug Therapy for Osteoporosis Kyoung Min Kim (Yonsei University, Korea)
Day 2
May 27(Fri)
13:25-14:15
Plenary Lecture 2 E
Channel 1 (Vista Hall 1) Overview
Denosumab is a monoclonal antibody against human RANKL that is widely used to inhibit bone resorption and reduce the risk of fracture in conditions such as osteoporosis, multiple myeloma, and cancer bone metastasis. However, its beneficial skeletal effects are reversed shortly after discontinuation due to the rapid increase of bone resorption often above the pre-treatment level, a phenomenon called “rebound resorption”. The reports of multiple vertebral fractures in some patients brought up clinical concerns but the underlying mechanisms are not clear yet. In this plenary session, Professor Charles O’Brien, University of Arkansas for Medical Sciences, will introduce his recent research on the mechanisms of rebound resorption using a mouse model of denosumab discontinuation and discuss the biological significance and clinical implications.
Chairperson(s)
Hong-Hee Kim (Seoul National Univsersity, Korea)
13:25-14:15 Osteoclast Formation; Who is in Control? Charles A. O’Brien (University of Arkansas for Medical Sciences, USA)
Day 2
May 27(Fri)
14:20-15:20
Oral Presentation 1 [Clinical] EK
Channel 1 (Vista Hall 1)
Chairperson(s)
Jung Min Koh (University of Ulsan, Korea), Hyun Sik Gong (Seoul National University, Korea)
14:20-14:30 Osteoporotic Fractures among Selective Estrogen Receptor Modulator Users in South Korea: Analysis Using National Claims Database Jung-Wee Park (Seoul National University Bundang Hospital, Korea)
14:30-14:40 Romosozumab is Associated with Greater Trabecular Score Improvement Compared to Denosumab in Postmenopausal Osteoporosis Namki Hong (Yonsei University, Korea)
14:40-14:50 The Adherence of Denosumab in Male Patients with Osteoporosis in Korea Chaiho Jeong (Division of Endocrinology and Metabolism, Department of Internal Medicine, Uijeongbu St. Marys Hospital, College of Medicine, The Catholic University of Korea, Korea)
14:50-15:00 Vertebral Fracture Prediction Model Using Images of Bone and Muscle from Abdominal Computed Tomography Sung Hye Kong (Seoul National University Bundang Hospital, Korea)
15:00-15:10 Real-world Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea Yusun Lee (Amgen, Korea)
15:10-15:20 Factors Associated with Compliance and Persistence to Pharmacotherapy in Korean Patients with Osteoporosis: A Nationwide Cohort Study Seong Hee Ahn (Inha University Hospital, Inha University School of Medicine, Korea)
Day 2
May 27(Fri)
15:30-16:45
Symposium 5. Application of Multi-Omics in Aging Research E
Channel 1 (Vista Hall 1)
Chairperson(s)
Gun-Il Im (Dongguk University, Korea), Sang Wan Kim (Seoul National University, Korea)
15:30-15:55 Large Scale Proteomic Profiling of Bones and Cartilage during Aging and Age-Related Diseases Birgit Schilling (Buck Institute for Research on Aging, USA)
15:55-16:20 Systems Biology of Multi-Omics for the Understanding of Human Microbiome and Metabolism Sunjae Lee (GIST, Korea)
16:20-16:45 Omics Profiling of Human Sarcopenia to Guide Innovation in Nutrition Science Jerome Feige (EPFL School of Life Sciences, Switzerland)
  • 한국로슈

Korean Society for Bone and Mineral Research (KSBMR)

#1001, Hyundai Kirim Bldg, 42, Seocho-daero 78-gil, Seocho-gu, Seoul, 06626, Korea

T. +82-2-3473-2230~1 | E. ksbmr@ksbmr.org

Business Registration Number: 106-82-62498 | Name of Representative: Yong-Chan Ha


SSBH 2022 Secretariat (PLANDO)

#1101, 220, Gonghang-daero, Gangseo-gu, Seoul, 07806, Republic of Korea

T. +82-2-6734-1011~3 | E. info@ssbh.co.kr


Copyright © by Korean Society for Bone and Mineral Research. All right reserved.

Go to Top